Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Gets OK to Float on NYSE

NEW YORK (GenomeWeb News) – Myriad Genetics today said that it has received approval to file an application transferring its shares from the Nasdaq stock exchange to the New York Stock Exchange.
 
The Salt Lake City-based developer of molecular diagnostics and therapeutics said that it expects to be trading on the NYSE Big Board in the second quarter of 2009. Once the transfer is complete, Myriad will trade under the symbol MGX.
 
Myriad had announced in October that it would spin off its drug development businesses from its molecular diagnostics business, creating two separate publicly traded firms. Myriad Pharmaceuticals will be listed on the NASDAQ Global Market under the company's current ticker symbol, MYGN.
 
Myriad officials recently said that the firm would likely use between $150 million and $200 million of the firm’s cash on hand to initially fund its pharma business.
 
 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.